Amgen/Chugai EPO patent case appeal
Executive Summary
Oral arguments were heard Sept. 7 before three-judge federal appeals panel in Washington, D.C. The judges gave no timetable for a ruling. The companies are appealing a Dec. 11 Boston federal court decision that found certain claims of Amgen and Genetics Institute's patents to be invalid but others to be valid. If that decision is upheld, Amgen would be enjoined from selling Epogen unless it allows Chugai on the market, according to an injunction issued in March.